Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aldeyra Therapeutics, Inc is a biotechnology business based in the US. Aldeyra Therapeutics shares (ALDX) are listed on the NASDAQ and all prices are listed in US Dollars. Aldeyra Therapeutics employs 8 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Social investors
| Latest market close | $12.52 |
|---|---|
| 52-week range | $5.53 - $14.62 |
| 50-day moving average | $10.70 |
| 200-day moving average | $11.65 |
| Wall St. target price | $25.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.00 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $12.52 from 2021-05-28
| 1 week (2021-07-25) | N/A |
|---|---|
| 1 month (2021-07-02) | 14.65% |
| 3 months (2021-05-05) | 4.59% |
| 6 months (2021-02-01) | N/A |
| 1 year (2020-08-01) | N/A |
|---|---|
| 2 years (2019-08-01) | N/A |
| 3 years (2018-08-01) | N/A |
| 5 years (2016-08-01) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -21.31% |
| Return on equity TTM | -45.98% |
| Profit margin | 0% |
| Book value | $2.65 |
| Market capitalisation | $519.8 million |
TTM: trailing 12 months
There are currently 5.8 million Aldeyra Therapeutics shares held short by investors – that's known as Aldeyra Therapeutics's "short interest". This figure is 4.4% down from 6.1 million last month.
There are a few different ways that this level of interest in shorting Aldeyra Therapeutics shares can be evaluated.
Aldeyra Therapeutics's "short interest ratio" (SIR) is the quantity of Aldeyra Therapeutics shares currently shorted divided by the average quantity of Aldeyra Therapeutics shares traded daily (recently around 1.1 million). Aldeyra Therapeutics's SIR currently stands at 5.33. In other words for every 100,000 Aldeyra Therapeutics shares traded daily on the market, roughly 5330 shares are currently held short.
However Aldeyra Therapeutics's short interest can also be evaluated against the total number of Aldeyra Therapeutics shares, or, against the total number of tradable Aldeyra Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aldeyra Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Aldeyra Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1237% of the tradable shares (for every 100,000 tradable Aldeyra Therapeutics shares, roughly 124 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aldeyra Therapeutics.
Find out more about how you can short Aldeyra Therapeutics stock.
We're not expecting Aldeyra Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aldeyra Therapeutics's shares have ranged in value from as little as $5.53 up to $14.6178. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aldeyra Therapeutics's is 1.7367. This would suggest that Aldeyra Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aldeyra Therapeutics, Inc. , a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
